Cellular Therapy and Hematologic Malignancies Grand Rounds
Date of Lecture:
October 7, 2014
Following this activity series, learners should be able to:
Title of Lecture: Journal Club: Acute GVHD Update
Speaker: Ashley Morris-Engemann, Pharm.D.
Time: 12:00 p.m. – 1:00 p.m.
Location: CR 7015 North Pavilion
*Please “view” attached journal articles for Journal Club conference. Ashley suggests not printing the articles as some of them are really long (the mycophenolate article is not in its final form, so it is 20 pages long!
Cutler, Cory, et al. Tacrolimus/sirolimus vs. tacrolimus/methotrexate as GvHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014:124(8):1372-1377.
Spoerl, S., et al. Activity of therapeutic JAK ½ blockade in graft-versus-host disease. Blood 2014:123(24):3832-3842.
Bolanos-Meade, J., et al. Phase III clinical trial steroids/mycophenylate Mofetil vs. steroids/plazebo as therapy for acute Graft-versus-Host Disease: BMT CTN 0802. Blood First Edition Paper, prepublished online August 28, 2014; DOI 10.1182/blood-2014-06-577023
Faculty (Speaker) Disclosure: Ashley Morris-Engemann, Pharm.D., has indicated she has no relationship with industry to disclose relative to the content of this CME activity.
Activity Medical Director/Planning Committee Disclosure(s): Dr. Mitchell Horwitz discloses the following personal/financial relationships which are relevant to this activity: Advisory Board Member for Genzyme; Principal Investigator for Otsuka and Pfizer.
Accreditation: The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The Duke University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)ä. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.